Neurodevelopmental disorders

TARGA imager
#Neurodevelopmental disorders #Organoids #Schizophrenia

Neurodevelopmental imaging in schizophrenia 

This paid-for advertorial by Lumencor appeared in DDW Volume 27 – Issue 3, Summer 2026. Studying neurodevelopmental disorders like schizophrenia is limited by model complexity and tissue access. Advanced stem cell models combined with high-speed imaging now enable scalable insight into neuronal activity and network behaviour.  Understanding neurodevelopment in schizophrenia remains a major… Read More

#Exclusive Content

TARGA imager
#App note #Imaging #Neurodevelopmental disorders #Neuroscience

App Note: Neurodevelopmental disease revealed with TARGA Imager

The study of neurodevelopmental diseases such as schizophrenia requires imaging tools capable of capturing complex neuronal behaviour at scale. This Application Note identifies Lumencor’s TARGA Imager enabling high-speed calcium imaging using NGN2 neurons and stem cell–derived neuronal models to study collective cellular dynamics with exceptional spatial and temporal resolution. Read More

#News

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

Research in genetics laboratory
#Francis Crick Institute #Genetics #Neurodevelopmental disorders #University of Oxford

Research uncovers previously unknown recessive condition 

Researchers have discovered how genetic mutations can cause neuro-developmental disorders, including a previously unknown recessive condition.  Scientists at the University of Oxford and the Francis Crick Institute, in collaboration with international partners, have made advances in understanding how mutations in a single non-coding gene contribute to neurodevelopmental… Read More

#News

#Neurodevelopmental disorders #Neuroscience #Phase III trial #Rare disease #UCB

UCB reports positive results for neurodevelopmental disorder

Global biopharmaceutical company UCB has reported positive data for its Phase III GEMZ study which is investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency Disorder (CDD).   The data were announced at the American Epilepsy Society (AES) meeting, Atlanta, USA.  The results… Read More

#Editor's Choice #News

#Genetics / genomics #Neurodevelopmental disorders #University of Oxford #Whole genome sequencing

Researchers discover genetic cause of neurodevelopment disorders

A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). NDD is a collective term for severe impairments in how the brain functions that impact learning, behaviour, speech, and movement. Read More

#News

Neurons in the brain
#Autism #Neurodevelopmental disorders #Neuroscience #Rutgers Health

Study of autism types reveals common underlying mechanism

An analysis of how brains with different forms of autism develop has revealed common underlying mechanisms that may respond to existing medications. For the study, Rutgers Health researchers used induced pluripotent stem cells to transform the blood cells of people with both genetic and idiopathic autism… Read More

#News

Neuroscience
#Autism #Gate Neurosciences #Neurodevelopmental disorders #Neuroscience #Preclinical investigations

Preclinical studies demonstrate potential of zelquistinel in autism

Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders. Gate Neurosciences has announced the publication of new peer-reviewed research demonstrating the therapeutic potential of zelquistinel (GATE-251) to address symptoms of autism spectrum disorder… Read More

#News

Preterm infant in the neonatal unit
#Brain #Financing #Neonatal #Neurodevelopmental disorders #Paediatrics #Start-ups #Tellus Therapeutics

Neonatal therapeutics company raises $35 million

Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.   The capital will be used to continue preclinical work conducted through the seed… Read More

#News #Start-up Zone

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Genetics / genomics #Neurodevelopmental disorders #Neurology #Precision medicine #Rare disease

Partnership hopes to advance precision drug development

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.  AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver… Read More

#News